Page 2 - Tolerance Network News Today

The work of Jeffrey Bluestone, who will be inducted into the Rutgers University Hall of Distinguished Alumni, has led to new treatments for cancer and autoimmune diseases.

Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors  Paris, February 22, 2024. At its meeting on February 22,...

This new data indicates that the peanut patch was efficacious and safe in children with peanut allergies in this age bracket, expanding the body of research on desensitization for toddlers and young children.

14.04.2023 - Zura Bio Limited (Nasdaq: “ZURA”) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced the appointment of Michael D. Howell, Ph.D., to the role ... Seite 1

New training and EHR support tool could help busy pediatric clinicians identify high-risk infants and implement latest feeding guidelines.

An experimental approach to enhancing a standard cat allergy treatment made it more effective and faster acting, and the benefits persisted for a year after treatment ended, a study supported by the National Institutes of Health has found. The findings were published in the Journal of Allergy and Clinical Immunology. Allergen immunotherapy, often called allergyAn experimental approach to enhancing a standard cat allergy treatment made it more effective and faster acting, and the benefits persist...

An experimental approach to enhancing a standard cat allergy treatment made it more effective and faster acting, and the benefits persisted for a year after treatment ended, a study supported by the National Institutes of Health has found.

Milwaukee, WI (PRWEB) October 10, 2022 -- A combination treatment of tezepelumab and allergen immunotherapy for patients with cat allergies resulted in

Inappropriate food IgE testing remains problematic but educating doctors and families and limiting food panel ordering can make a difference.

Children with a peanut allergy could overcome it, according to a study, "Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the Immune Tolerance Network IMPACT trial)," a randomized placebo-controlled study published in The Lancet.